Scan of a brain with Alzheimer's (Getty Images)
Facing a tepid Alzheimer’s market, Lilly looks to build ‘a sense of urgency’ to jumpstart sales of donanemab
On paper, Alzheimer’s disease should be an uncomplicated market for drugmakers. There are millions of potential patients, who until recently had no real option for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
